CIM
CRL icon

Confluence Investment Management’s Charles River Laboratories CRL Stock Holding History

Confluence Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.8M Sell
91,632
-8,902
-9% -$1.59M 0.32% 82
2026
Q1 		$17.3M Sell
100,534
-5,092
-5% -$944K 0.27% 87
2025
Q4 		$21.1M Buy
105,626
+9,663
+10% +$1.75M 0.32% 75
2025
Q3 		$15M Sell
95,963
-1,263
-1% -$201K 0.21% 95
2025
Q2 		$14.8M Buy
97,226
+700
+0.7% +$93.3K 0.21% 99
2025
Q1 		$14.5M Buy
96,526
+3,522
+4% +$590K 0.21% 97
2024
Q4 		$17.2M Sell
93,004
-1,955
-2% -$377K 0.24% 94
2024
Q3 		$18.7M Sell
94,959
-313
-0.3% -$65K 0.25% 91
2024
Q2 		$19.7M Sell
95,272
-1,685
-2% -$382K 0.28% 83
2024
Q1 		$26.3M Sell
96,957
-257
-0.3% -$61.4K 0.35% 72
2023
Q4 		$23M Sell
97,214
-3,185
-3% -$626K 0.32% 77
2023
Q3 		$19.7M Buy
100,399
+16,398
+20% +$3.37M 0.3% 81
2023
Q2 		$17.7M Buy
+84,001
New +$16.7M 0.26% 90
2021
Q4 		– Sell
-125,409
Closed -$51.8M – 308
2021
Q3 		$51.8M Sell
125,409
-59,972
-32% -$24.9M 0.73% 54
2021
Q2 		$68.6M Sell
185,381
-10,503
-5% -$3.51M 0.91% 45
2021
Q1 		$56.8M Sell
195,884
-229
-0.1% -$63.7K 0.8% 46
2020
Q4 		$49M Sell
196,113
-3,116
-2% -$742K 0.73% 49
2020
Q3 		$45.1M Sell
199,229
-7,616
-4% -$1.58M 0.73% 47
2020
Q2 		$36.1M Buy
206,845
+40,479
+24% +$6.46M 0.6% 56
2020
Q1 		$21M Buy
+166,366
New +$25M 0.4% 71

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Confluence Investment Management's CRL Position: Q2 2026 in Review

Confluence Investment Management reduced its Charles River Laboratories (CRL) stake by 8.9% in Q2 2026, selling an estimated $1.59M and leaving 91,632 shares worth $20.8M. The position accounts for 0.32% of the portfolio, ranked #82.

Confluence Investment Management first reported a position in CRL in Q1 2020 and has held it in 20 quarters since. The position peaked at $68.6M in Q2 2021. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Confluence Investment Management held 91,632 shares of Charles River Laboratories worth $20.8M as of Q2 2026.
  • Confluence Investment Management sold 8,902 Charles River Laboratories shares in Q2 2026, an estimated $1.59M.
  • Charles River Laboratories made up 0.32% of Confluence Investment Management's portfolio in Q2 2026, its #82 holding.
  • Confluence Investment Management first reported a position in Charles River Laboratories in Q1 2020 and has held it in 20 quarters since.
  • Confluence Investment Management's Charles River Laboratories position peaked at $68.6M in Q2 2021.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Confluence Investment Management's 13F filing for Q2 2026, filed 1 Jul 2026.